Immunogenicity and protective efficacy offered by a ribosomal-based vaccine from Shigella flexneri 2a

Shim, Doo-Hee; Chang, Shau‐Jin; Park, Sung-Moo; Jang, Han Byul; Carbis, Rodney; Czerkinsky, Cécil; Uematsu, Satoshi; Akira, Shizuo; Kweon, Mi‐Na

doi:10.1016/j.vaccine.2007.03.050

Cited by 21 publications

(15 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several groups have explored different approaches in the search of a Shigella vaccine. These include live attenuated strains of Shigella (16), LPS-protein conjugates (17), mixtures of subunit components (18), and recombinant proteins (19). Our hypothesis is that a vaccine comprised of highly conserved protein antigens would provide broad, serotype-independent protection, thus bypassing the need to consider multiple serotypes as are needed for vaccines that target LPS or O antigen.…”

mentioning

confidence: 99%

Characterization of a Novel Fusion Protein from IpaB and IpaD of Shigella spp. and Its Potential as a Pan-Shigella Vaccine

et al. 2013

View full text Add to dashboard Cite

Shigellosis is an important disease in the developing world, where about 90 million people become infected with Shigella spp. each year. We previously demonstrated that the type three secretion apparatus (T3SA) proteins IpaB and IpaD are protective antigens in the mouse lethal pulmonary model. In order to simplify vaccine formulation and process development, we have evaluated a vaccine design that incorporates both of these previously tested Shigella antigens into a single polypeptide chain. To determine if this fusion protein (DB fusion) retains the antigenic and protective capacities of IpaB and IpaD, we immunized mice with the DB fusion and compared the immune response to that elicited by the IpaB/IpaD combination vaccine. Purification of the DB fusion required coexpression with IpgC, the IpaB chaperone, and after purification it maintained the highly ␣-helical characteristics of IpaB and IpaD. The DB fusion also induced comparable immune responses and retained the ability to protect mice against Shigella flexneri and S. sonnei in the lethal pulmonary challenge. It also offered limited protection against S. dysenteriae challenge. Our results show the feasibility of generating a protective Shigella vaccine comprised of the DB fusion.

show abstract

mentioning

confidence: 99%

Characterization of a Novel Fusion Protein from IpaB and IpaD of Shigella spp. and Its Potential as a Pan-Shigella Vaccine

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Interestingly, robust levels of Shigella-derived LPS-specific IgG and IgA Abs and antibody-forming cells were elicited in systemic and mucosal compartments following two intranasal administrations of SRV. Groups of mice receiving intranasal SRV developed milder pulmonary pneumonia upon challenge with virulent S. flexneri 2a than did those receiving parenteral SRV [72].…”

Section: Plant Peptides and Proteinsmentioning

confidence: 89%

Targeting Colon Drug Delivery by Natural Products

Kim¹

2012

Inflammatory Bowel Disease

View full text Add to dashboard Cite

“…The best prophylactic measure probably would be to prevent the invasion of wild type virulent Shigellae strains into the epithelial cell of large intestine which may limit their intracellular multiplication and spread in the tissues (Sansonetti et al 1991). A live attenuated Shigella strain, expressing LPS and a few selected Ipa antigens (Shaikh et al 1995), has been suggested for successful vaccine formulation and should be ideally preferred (Pal and Lindberg 1996). Black et al (1987) conjugally transferred the invasion plasmid carrying LPS biosynthesis genes of S. sonnei into Salmonella typhi Ty21a.…”

Section: Discussionmentioning

confidence: 99%

“…Our earlier studies (Biswas et al 1999;Hens et al 2003) documented that cell surface antigens like LPS, OMPs express antibacterial immunity. It has been reported that bacillary dysentery infection reacts with a strong Oantigen and the Ipa of the outer membrane represents the major immune stimulating moieties on the surface of Shigella (Chowers et al 2007;Shim et al 2007).…”

Section: Discussionmentioning

confidence: 99%

“…But; however, in a developing country like India, the sanitation problem is acute. For more than 50 years, scientists have been trying to come up with suitable candidate vaccines such as inactivated Shigella vaccines (Osorio et al 2007), live attenuated vaccines (Venkatesan and Ranallo 2006;Ranallo et al 2007;McKenzie et al 2008;Sadorge et al 2008), ribosomal-based vaccines (Shim et al 2007) and conjugate vaccines (Cohen et al 1997;Chowers et al 2007) against shigellosis. In our previous two publications (Biswas et al 1999;Hens et al 2003), we have shown that Shigella dysenteriae type 1 (LTSH) strain carrying lipopolysaccharide (LPS) biosynthesis gene of Salmonella enterica serover typhimurium was unable to invade the HeLa cell and rabbit intestinal mucosa, and it was Sereny negative.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The efficacy and immunogenicity of a live transconjugant hybrid strain of Shigella dysenteriae type 1 in two animal models

Koley

Barman

Roy

et al. 2008

World J Microbiol Biotechnol

View full text Add to dashboard Cite

In our earlier studies, we constructed a hybrid strain of Shigella dysenteriae type 1 by introducing a plasmid vector pPR 1347. After introduction of a lipopolysaccharide (LPS) biosynthesis gene, virulent Shigella dysenteriae type 1 strain became avirulent. In our present study, we have evaluated the immune response and protective efficacy of avirulent live transconjugant Shigella hybrid (LTSH) strain against wild type Shigella dysenteriae type 1, after four doses of oral (rabbit) and intranasal (mouse) immunizations. Serum IgG titers showed exponential increase during immunization and peaking on the 28th day and remained at that level till the 35th day in both the rabbit and the mouse models. When tested, serum IgG titers persisted for 63 days in mice and relatively high for 150 days in case of rabbits. Protection studies showed 100% protection against the challenge with wild type Shigella dysenteriae type 1 strain in rabbits and 80% protection in mice. Our results suggested that the LTSH strain could be a useful vaccine candidate strain in the future.

show abstract

Immunogenicity and protective efficacy offered by a ribosomal-based vaccine from Shigella flexneri 2a

Cited by 21 publications

References 31 publications

Characterization of a Novel Fusion Protein from IpaB and IpaD of Shigella spp. and Its Potential as a Pan-Shigella Vaccine

Characterization of a Novel Fusion Protein from IpaB and IpaD of Shigella spp. and Its Potential as a Pan-Shigella Vaccine

Targeting Colon Drug Delivery by Natural Products

The efficacy and immunogenicity of a live transconjugant hybrid strain of Shigella dysenteriae type 1 in two animal models

Contact Info

Product

Resources

About